Short-Term Diabetes Remission Outcomes in Patients with BMI ≤ 30 kg/m2 Following Sleeve Gastrectomy

  • Jason Widjaja
  • Haixing Pan
  • Ponnie Robertlee Dolo
  • Libin Yao
  • Chao Li
  • Yong Shao
  • Xiaocheng ZhuEmail author
Original Contributions



Sleeve gastrectomy (SG) has become the most popular bariatric procedure. Although bariatric surgery is recommended for type 2 diabetes mellitus (T2DM) in Asian patients with BMI 27.5–32.4 kg/m2, reported evidences, especially following SG, are still lacking.


Patients’ data from June 2016 to June 2018 that underwent SG as primary surgery at our setting were analyzed. Patients with T2DM, without insulin use and BMI 27.5–30 kg/m2, were our main criteria. Preoperative and postoperative parameters were as such: age, BMI, T2DM duration, anti-diabetic medications, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), insulin, C-peptide, and homeostatic model assessment-insulin resistance (HOMA-IR). Follow-up duration was at 1, 3, 6, and 12 months.


Eighteen patients (7 male and 11 female) were presented for this study. The mean age and diabetes duration were 46.3 ± 11.9 years and 31.8 ± 26.5 months, respectively. The mean preoperative vs postoperative 12-month assessment was as such: BMI 29.3 ± 0.9 vs 23.9 ± 0.9 kg/m2, FPG 8.4 ± 3.1 vs 5.6 ± 0.7 mmol/L, HbA1c 8.3 ± 1.8 vs 5.9 ± 0.7%, insulin 103.9 ± 47.4 vs 53.9 ± 13.1 pmol/L, C-peptide 1.90 ± 1.22 vs 1.08 ± 0.44 ng/ml, and HOMA-IR 5.5 ± 4.0 vs 1.9 ± 0.6, all reached statistical significance (p value < 0.05).


In short-term, and also under strict selection criteria, SG can result in both improvement and remission of T2DM in patients with BMI 27.5–30 kg/m2. Larger sample size and longer follow-up duration will be needed in the future.


Bariatric surgery Sleeve gastrectomy Type 2 diabetes mellitus Low BMI Diabetes remission 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

For this retrospective study, additional formal consent is not required.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Diabetes Mellitus – epidemiology. 2. Diabetes Mellitus – prevention and control. 3. Diabetes, Gestational. 4. Chronic Disease. 5. Public Health. I. World Health Organization. ISBN 978 92 4 156525 7 (NLM classification: WK 810).Google Scholar
  2. 2.
    American Diabetes Association. 7. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S65–72.CrossRefGoogle Scholar
  3. 3.
    Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and metaanalysis. Am J Med. 2009;122:248–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Haruta H, Kasama K, Ohta M, et al. Long-term outcomes of bariatric and metabolic surgery in Japan: results of a multi-institutional survey. Obes Surg. 2017;27(3):754–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Dicker D, Yahalom R, Comaneshter DS, et al. Long-term outcomes of three types of bariatric surgery on obesity and type 2 diabetes control and remission. Obes Surg. 2016;26(8):1814–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24(3):437–55.CrossRefPubMedGoogle Scholar
  7. 7.
    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641–51.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–27.CrossRefGoogle Scholar
  9. 9.
    Goodpaster BH, Sparks LM. Metabolic flexibility in health and disease. Cell Metab. 2017;25(5):1027–36.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.CrossRefGoogle Scholar
  11. 11.
    Casajoana A, Pujol J, Garcia A, et al. Predictive value of gut peptides in T2D remission: randomized controlled trial comparing metabolic gastric bypass, sleeve gastrectomy and greater curvature plication. Obes Surg. 2017;27(9):2235–45.CrossRefPubMedGoogle Scholar
  12. 12.
    Lager CJ, Esfandiari NH, Subauste AR, et al. Roux-En-Y gastric bypass vs. sleeve gastrectomy: balancing the risks of surgery with the benefits of weight loss. Obes Surg. 2017;27(1):154–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Keidar A, Hershkop KJ, Marko L, et al. Roux-en-Y gastric bypass vs sleeve gastrectomy for obese patients with type 2 diabetes: a randomised trial. Diabetologia. 2013;56(9):1914–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Nocca D, Guillaume F, Noel P, et al. Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg. 2011;21(6):738–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Murphy R, Clarke MG, Evennett NJ, et al. Laparoscopic sleeve gastrectomy versus banded Roux-en-Y gastric bypass for diabetes and obesity: a prospective randomised double-blind trial. Obes Surg. 2018;28(2):293–302.CrossRefPubMedGoogle Scholar
  16. 16.
    Ahuja A, Tantia O, Chaudhuri T, et al. Predicting remission of diabetes post metabolic surgery: a comparison of ABCD, diarem, and DRS scores. Obes Surg. 2018;28(7):2025–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Liang H, Cao Q, Liu H, et al. The predictive factors for diabetic remission in Chinese patients with BMI > 30 kg/m2 and BMI < 30 kg/m2 are different. Obes Surg. 2018;28(7):1943–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zhu J, Gupta R, Safwa M. The mechanism of metabolic surgery: gastric center hypothesis. Obes Surg. 2016;26(7):1639–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim DJ, Paik KY, Kim MK, et al. Three-year result of efficacy for type 2 diabetes mellitus control between laparoscopic duodenojejunal bypass compared with laparoscopic Roux-en-Y gastric bypass. Ann Surg Treat Res. 2017;93(5):260–5.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Oberbach A, Schlichting N, Heinrich M, et al. Gastric mucosal devitalization reduces adiposity and improves lipid and glucose metabolism in obese rats. Gastrointest Endosc. 2018;87(1):288–299.e6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of General SurgeryThe Affiliated Hospital of Xuzhou Medical UniversityXuzhouPeople’s Republic of China

Personalised recommendations